BWX’s first quarter results for 2026 exceeded Wall Street’s expectations for both revenue and non-GAAP earnings, but the market reaction was notably negative. Management attributed the performance to higher throughput, strong operational execution, and robust demand in both government and commercial segments. CEO Rex Geveden pointed to “improved throughput, favorable pacing of work, and exceptional operational execution” as major contributors. The company also highlighted a significant year-over-year increase in backlog, which management believes offers clear visibility for future growth.
Is now the time to buy BWXT? Find out in our full research report (it’s free for active Edge members).
BWX (BWXT) Q1 CY2026 Highlights:
- Revenue: $860.2 million vs analyst estimates of $837.3 million (26.1% year-on-year growth, 2.7% beat)
- Adjusted EPS: $1.12 vs analyst estimates of $0.93 (21% beat)
- Adjusted EBITDA: $148 million vs analyst estimates of $134.8 million (17.2% margin, 9.8% beat)
- Management raised its full-year Adjusted EPS guidance to $4.68 at the midpoint, a 1.1% increase
- EBITDA guidance for the full year is $657.5 million at the midpoint, above analyst estimates of $651.3 million
- Operating Margin: 12.4%, down from 14.2% in the same quarter last year
- Backlog: $8.65 billion at quarter end, up 77.3% year on year
- Market Capitalization: $18.81 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From BWX’s Q1 Earnings Call
- Matthew Akers (BNP Paribas): Asked about the price and strategic rationale for the PCG acquisition. CFO Michael Fitzgerald clarified the price was around $200 million and emphasized both capacity needs and workforce quality as drivers for the acquisition.
- Jeffrey Campbell (Seaport Research Partners): Inquired about limitations of the new commercial facility and its ability to serve different nuclear customers. Fitzgerald explained the planned facility would have no such limitations and would be structured as a center of excellence for various component types.
- Marc Bianchi (TD Cowen): Asked about BWX’s competitive positioning in TRISO fuel and expansion plans. CEO Rex Geveden explained BWX is currently the only producer at scale, with plans for further capacity to bring down costs and support broader commercial deployment.
- Bob Labick (CGS Securities): Sought detail on the scale and timeline for U.S. capacity expansion, including capital intensity. Geveden and Fitzgerald described ongoing expansion at the Cambridge plant and outlined expectations for the Mount Vernon buildout, noting a multi-year timeline and higher costs for greenfield projects.
- Joshua Korn (Wells Fargo): Queried about medical segment growth drivers and the status of Tc-99. Geveden highlighted ongoing strength across medical isotopes, with new products like lead-212 in the pipeline, and said Tc-99 remains in development with no contribution forecast for this year.
Catalysts in Upcoming Quarters
Over the next few quarters, the StockStory team will closely monitor (1) the pace of U.S. manufacturing expansion, including progress on the Mount Vernon facility and the integration of PCG, (2) the conversion of backlog into revenue, especially in commercial and government nuclear projects, and (3) continued growth in advanced nuclear fuel and medical isotope businesses. Further signs of customer preference for localized nuclear supply chains and new contract wins will also be key indicators.
BWX currently trades at $205.49, down from $216.68 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
